학술논문
Correlation of commercially available quantitative MGMT(O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival.
Document Type
Article
Author
Source
Neuro-Oncology Practice; May 2019, Vol. 6 Issue: 3 p194-202, 9p
Subject
Language
ISSN
20542577; 20542585
Abstract
Between 2011 and 2016, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation testing at University of California Los Angeles (UCLA) was performed through LabCorp, using a threshold of 2 to distinguish MGMTmethylated from unmethylated tumors. In this study, we sought to determine whether the magnitude of the methylation score correlated with outcome.